Neutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one month

buir.contributor.authorSeker, Urartu Ozgur Safak
buir.contributor.authorKehribar, Ebru Sahin
buir.contributor.authorAhan, Recep Erdem
buir.contributor.authorAslan, Volkan
buir.contributor.orcidSeker, Urartu Ozgur Safak |0000-0002-5272-1876
buir.contributor.orcidKehribar, Ebru Sahin| 0000-0003-2951-4390
buir.contributor.orcidAhan, Recep Erdem| 0000-0002-6061-9062
buir.contributor.orcidAslan, Volkan | 0000-0001-7989-0592
dc.citation.epage18en_US
dc.citation.issueNumber1en_US
dc.citation.spage9en_US
dc.citation.volumeNumber47en_US
dc.contributor.authorBastug, Aliye
dc.contributor.authorBodur, Hurrem
dc.contributor.authorUrartu Ozgur Safak, Seker
dc.contributor.authorFilazi, Nazlican
dc.contributor.authorAydos, Omer
dc.contributor.authorEbru Sahin, Kehribar
dc.contributor.authorHanifehnezhad, Ali Reza
dc.contributor.authorKazancioglu, Sumeyye
dc.contributor.authorRecep Erdem, Ahan
dc.contributor.authorVolkan, Aslan
dc.contributor.authorCakir, Banu
dc.contributor.authorSertcelik, Ahmet
dc.contributor.authorOzkul, Aykut
dc.date.accessioned2023-02-24T11:44:19Z
dc.date.available2023-02-24T11:44:19Z
dc.date.issued2022-01-20
dc.departmentInstitute of Materials Science and Nanotechnology (UNAM)en_US
dc.description.abstractBackground: There is a knowledge gap about the characteristics of neutralizing antibody (NAb) response in patients who recovered COVID-19. In this study, it is aimed to elucidate the factors affecting the presence and titers of antibodies up to 30-days after onset. Material and methods: A total of 129 laboratory-confirmed COVID-19 patients were enrolled. Clinical data were obtained retrospectively. SARS-CoV-2 specific NAb, IgM, and IgG antibody responses were analyzed. Results: SARS-CoV-2 specific NAb, IgM and IgG, were detected at the time of hospital discharge in 60.5%, 30.2%, and 51.9% of the patients, respectively. The median time for obtaining serum samples for antibody tests after symptoms’ onset was 11 days. The median titer of neutralizing antibody (SN50) was significantly higher in severe patients (25 vs. 7.5, p=0.009). Of the 23 severe patients, 52.2% (n=12) had higher NAb titers (i.e., SN50≥1:25) when compared to that in non-severe patients (OR=2.89; 95%CI=1.15–7.28, p=0.021), yet, the potential effect of follow-up time on NAb status and titers could not be ruled out. Conclusions: The presence of antibody response is not the only determinative factor for recovery. The presence and higher titers of NAb were detected more in severe patients than their non-severe counterparts. Survival analysis suggested that this difference could at least be partially explained by the length of follow-up through antibody testing (at discharge) after symptoms’ onset.en_US
dc.identifier.doi10.1515/tjb-2021-0200en_US
dc.identifier.eissn1303-829X
dc.identifier.issn0250-4685
dc.identifier.urihttp://hdl.handle.net/11693/111684
dc.language.isoEnglishen_US
dc.publisherWalter de Gruyter GmbHen_US
dc.relation.isversionofhttps://doi.org/10.1515/tjb-2021-0200en_US
dc.source.titleTurk Biyokimya Dergisien_US
dc.subjectAntibody responseen_US
dc.subjectCOVID-19en_US
dc.subjectHumoral immunityen_US
dc.subjectIgM and IgGen_US
dc.subjectNeutralizing antibodiesen_US
dc.titleNeutralizing antibody response and associated factors in Coronavirus-19 disease (COVID-19) up to one monthen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
Neutralizing_antibody_response_and_associated_factors_in_Coronavirus-19_disease_(COVID-19)_up_to_one_month.pdf
Size:
1.15 MB
Format:
Adobe Portable Document Format
Description:
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.69 KB
Format:
Item-specific license agreed upon to submission
Description: